Pāriet uz galveno navigāciju Pāriet uz meklēšanu Pāriet uz galveno saturu

Advancing 6-bromo-7-[11C]methylpurine to clinical use: improved regioselective radiosynthesis, non-clinical toxicity data and human dosimetry estimates

  • Severin Mairinger*
  • , Matthias Jackwerth
  • , Ondřej Soukup
  • , Matthias Blaickner
  • , Clemens Decristoforo
  • , Lukas Nics
  • , Jens Pahnke
  • , Marcus Hacker
  • , Markus Zeitlinger
  • , Oliver Langer
  • *Šī darba korespondējošais autors
  • Medical University of Vienna
  • Charles University
  • University of Applied Sciences Technikum Wien
  • Innsbruck Medical University
  • Tel Aviv University
  • Universitaetsklinikum Schleswig-Holstein
  • University of Oslo

Zinātniskās darbības rezultāts: Devums žurnālam › Zinātniskais raksts (žurnālā) › koleģiāli recenzēts

2 Atsauces (Scopus)

Kopsavilkums

Background: 6-Bromo-7-[11C]methylpurine ([11C]BMP) is a radiotracer for positron emission tomography (PET) to measure multidrug resistance-associated protein 1 (MRP1) transport activity in different tissues. Previously reported radiosyntheses of [11C]BMP afforded a mixture of 7- and 9-[11C]methyl regioisomers. To prepare for clinical use, we here report an improved regioselective radiosynthesis of [11C]BMP, the results of a non-clinical toxicity study as well as human dosimetry estimates based on mouse PET data. Results: [11C]BMP was synthesised by regioselective N7-methylation of 6-bromo-7H-purine (prepared under good manufacturing practice) with [11C]methyl triflate in presence of 2,2,6,6-tetramethylpiperidine magnesium chloride in a TRACERlab™ FX2 C synthesis module. [11C]BMP was obtained within a total synthesis time of approximately 43 min in a decay-corrected radiochemical yield of 20.5 ± 5.2%, based on starting [11C]methyl iodide, with a radiochemical purity > 99% and a molar activity at end of synthesis of 197 ± 130 GBq/μmol (n = 28). An extended single-dose toxicity study conducted in male and female Wistar rats under good laboratory practice after single intravenous (i.v.) administration of unlabelled BMP (2 mg/kg body weight) revealed no test item related adverse effects. Human dosimetry estimates, based on dynamic whole-body PET data in female C57BL/6J mice, suggested that an i.v. injected activity amount of 400 MBq of [11C]BMP will deliver an effective dose in the typical range of 11C-labelled radiotracers. Conclusions: [11C]BMP can be produced in sufficient amounts and acceptable quality for clinical use. Data from the non-clinical safety evaluation showed no adverse effects and suggested that the administration of [11C]BMP will be safe and well tolerated in humans.

OriģinālvalodaAngļu
Raksta numurs34
Lapas (no-līdz)1-13
ŽurnālsEJNMMI Radiopharmacy and Chemistry
Sējums9
Izdevuma numurs1
DOIs
Publikācijas statussPublicēts - dec. 2024

ANO IAM

Šis izpildes rezultāts palīdz sasniegt šādus ANO ilgtspējīgas attīstības mērķus (IAM)

  1. 9. IAM — Rūpniecība, Inovācija un Infrastruktūra
    9. IAM — Rūpniecība, Inovācija un Infrastruktūra

OECD Zinātnes nozare

  • 3.1 Medicīnas bāzes zinātnes, tai skaitā farmācija

Nospiedums

Uzziniet vairāk par pētniecības tēmām “Advancing 6-bromo-7-[11C]methylpurine to clinical use: improved regioselective radiosynthesis, non-clinical toxicity data and human dosimetry estimates”. Kopā tie veido unikālu nospiedumu.

Citēt šo